• 1. An atom-economical protocol for direct conversion of Baylis–Hillman alcohols to β-chloro aldehydes in water?
  Raktani Bikshapathi,Sai Prathima Parvathaneni,Vaidya Jayathirtha Rao Green Chem., 2017,19, 4446-4450
• 2. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 3. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 4. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 5. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Straight chain fatty acids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates Straight chain fatty acids

Research Briefing on 4-((ethoxycarbonyl)(methyl)amino)butanoic acid (CAS: 1152498-18-4) in Chemical Biology and Pharmaceutical Applications

The compound 4-((ethoxycarbonyl)(methyl)amino)butanoic acid (CAS: 1152498-18-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug design and synthesis. This briefing provides an overview of the latest research developments, focusing on its structural properties, synthetic pathways, and potential therapeutic applications. The compound's unique chemical structure, featuring both an ethoxycarbonyl group and a methylamino moiety, makes it a valuable intermediate in the development of novel bioactive molecules.

Recent studies have highlighted the role of 4-((ethoxycarbonyl)(methyl)amino)butanoic acid as a key building block in the synthesis of prodrugs and enzyme inhibitors. For instance, researchers have utilized this compound to develop targeted therapies for neurological disorders, leveraging its ability to cross the blood-brain barrier. Additionally, its incorporation into peptide-based drug candidates has shown promise in enhancing bioavailability and metabolic stability. The compound's compatibility with various coupling reagents and protecting groups further underscores its utility in complex synthetic routes.

In a groundbreaking study published in the Journal of Medicinal Chemistry, scientists demonstrated the efficacy of derivatives of 4-((ethoxycarbonyl)(methyl)amino)butanoic acid in modulating GABAergic neurotransmission. The study employed advanced computational modeling and in vitro assays to elucidate the compound's binding affinity for GABA receptors, paving the way for its potential use in treating anxiety and epilepsy. These findings are particularly noteworthy given the growing demand for safer and more effective neuroactive agents.

Another area of active research involves the application of 4-((ethoxycarbonyl)(methyl)amino)butanoic acid in cancer therapeutics. Recent preclinical trials have explored its role as a linker in antibody-drug conjugates (ADCs), where it facilitates the targeted delivery of cytotoxic payloads to tumor cells. The compound's stability under physiological conditions and its ability to undergo controlled cleavage in the tumor microenvironment make it an attractive candidate for ADC development. These advancements align with the broader industry trend toward precision medicine and personalized cancer treatments.

Despite these promising developments, challenges remain in optimizing the pharmacokinetic and pharmacodynamic properties of 4-((ethoxycarbonyl)(methyl)amino)butanoic acid-based compounds. Researchers are actively investigating strategies to mitigate potential off-target effects and improve metabolic stability. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of these findings into clinical applications. Future research directions may include exploring the compound's utility in other therapeutic areas, such as infectious diseases and autoimmune disorders.

In conclusion, 4-((ethoxycarbonyl)(methyl)amino)butanoic acid (CAS: 1152498-18-4) represents a versatile and promising scaffold in chemical biology and drug discovery. Its applications span from neuroactive agents to targeted cancer therapies, reflecting its broad potential in addressing unmet medical needs. Continued research and innovation in this area are likely to yield significant breakthroughs, further solidifying its role in the pharmaceutical industry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)